ATE496635T1 - Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sind - Google Patents
Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sindInfo
- Publication number
- ATE496635T1 ATE496635T1 AT02739838T AT02739838T ATE496635T1 AT E496635 T1 ATE496635 T1 AT E496635T1 AT 02739838 T AT02739838 T AT 02739838T AT 02739838 T AT02739838 T AT 02739838T AT E496635 T1 ATE496635 T1 AT E496635T1
- Authority
- AT
- Austria
- Prior art keywords
- therapy
- methods
- antestrogen
- inhibiting
- compositions
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004565 tumor cell growth Effects 0.000 title 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 3
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 3
- 239000000328 estrogen antagonist Substances 0.000 abstract 3
- 102100037632 Progranulin Human genes 0.000 abstract 2
- 101710114165 Progranulin Proteins 0.000 abstract 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measurement Of Resistance Or Impedance (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/880,842 US6881548B2 (en) | 1997-05-23 | 2001-06-15 | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
PCT/US2002/018550 WO2002102306A2 (en) | 2001-06-15 | 2002-06-14 | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE496635T1 true ATE496635T1 (de) | 2011-02-15 |
Family
ID=25377233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02739838T ATE496635T1 (de) | 2001-06-15 | 2002-06-14 | Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sind |
Country Status (12)
Country | Link |
---|---|
US (1) | US6881548B2 (de) |
EP (2) | EP1399739B1 (de) |
JP (5) | JP4348178B2 (de) |
KR (3) | KR101258254B1 (de) |
CN (2) | CN100397081C (de) |
AT (1) | ATE496635T1 (de) |
AU (2) | AU2002315060B2 (de) |
CA (2) | CA2450590A1 (de) |
DE (1) | DE60239059D1 (de) |
ES (2) | ES2531368T3 (de) |
HK (1) | HK1083366A1 (de) |
WO (2) | WO2002102306A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100111928A1 (en) * | 1997-05-23 | 2010-05-06 | A & G Pharmaceutical, Inc. | Methods and kits for diagnosis tumorgenicity |
US6309826B1 (en) * | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
US8512960B2 (en) * | 1997-05-23 | 2013-08-20 | A&G Pharmaceutical, Inc. | 88kDa tumorigenic growth factor and antagonists |
US20030215445A1 (en) | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
ATE483724T1 (de) * | 2003-02-26 | 2010-10-15 | A & G Pharmaceuticals Inc | Verfahren zur erhöhung der ausbreitung von b- zellen |
EP1849480A3 (de) * | 2003-06-23 | 2013-06-26 | A & G Pharmaceutical, Inc. | Zusammensetzungen und Verfahren zur Wiederherstellung der Empfindlichkeit von Tumorzellen gegen die Antitumorbehandlung und zur Induzierung von Apoptose |
US7368428B2 (en) * | 2003-06-23 | 2008-05-06 | A&G Pharmaceutical, Inc. | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
JP2007517763A (ja) * | 2003-08-01 | 2007-07-05 | エイアンドジー ファーマスーティカル インコーポレイテッド | Her2アンタゴニストを用いた治療への感受性を回復させる組成物および方法 |
EP2173981B1 (de) | 2007-06-13 | 2018-07-18 | 3M Innovative Properties Company | Sicherbares montagematerial sowie verfahren zu seiner herstellung und verwendung |
GB2474146B (en) * | 2008-04-29 | 2013-04-10 | Nodality Inc | Methods of determining the health status of an individual |
WO2010028373A2 (en) * | 2008-09-05 | 2010-03-11 | A&G Pharmaceutical, Inc. | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients |
EP2844131B1 (de) | 2012-05-03 | 2017-10-11 | Medial Research Ltd. | Verfahren und systeme zur bestimmung des risikos von gastrointestinalem krebs |
JP6148540B2 (ja) * | 2013-06-07 | 2017-06-14 | 株式会社島津製作所 | 質量分析装置を用いたグラニュリンペプチドの定量分析方法、および分析用プログラム |
AU2016294526A1 (en) * | 2015-07-14 | 2018-02-08 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
IL272924B2 (en) | 2017-09-11 | 2024-01-01 | Atossa Therapeutics Inc | Methods for preparing and using endoxifen |
US20220362771A1 (en) * | 2018-07-13 | 2022-11-17 | Hifibio Sas | Use of droplet single cell epigenome profiling for patient stratification |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5416192A (en) | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
CA2023030A1 (en) * | 1990-07-13 | 1992-01-14 | Robert R. Guerrero | In vitro method and probe for detecting the presence of the ring shaped particle and malignancy in humans and animals |
US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
US6309826B1 (en) | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
DE60106281T2 (de) | 2000-08-11 | 2005-02-24 | Wyeth | Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms |
-
2001
- 2001-06-15 US US09/880,842 patent/US6881548B2/en not_active Expired - Lifetime
-
2002
- 2002-06-14 KR KR1020107008529A patent/KR101258254B1/ko not_active IP Right Cessation
- 2002-06-14 ES ES02741997T patent/ES2531368T3/es not_active Expired - Lifetime
- 2002-06-14 KR KR1020037016437A patent/KR100972053B1/ko not_active IP Right Cessation
- 2002-06-14 JP JP2003504895A patent/JP4348178B2/ja not_active Expired - Fee Related
- 2002-06-14 CN CNB028158040A patent/CN100397081C/zh not_active Expired - Lifetime
- 2002-06-14 CA CA002450590A patent/CA2450590A1/en not_active Abandoned
- 2002-06-14 AT AT02739838T patent/ATE496635T1/de not_active IP Right Cessation
- 2002-06-14 CN CN200810092887.6A patent/CN101584862B/zh not_active Expired - Fee Related
- 2002-06-14 EP EP02741997.7A patent/EP1399739B1/de not_active Expired - Lifetime
- 2002-06-14 AU AU2002315060A patent/AU2002315060B2/en not_active Ceased
- 2002-06-14 EP EP02739838A patent/EP1404365B1/de not_active Expired - Lifetime
- 2002-06-14 CA CA002450666A patent/CA2450666A1/en not_active Abandoned
- 2002-06-14 AU AU2002312462A patent/AU2002312462B2/en not_active Ceased
- 2002-06-14 WO PCT/US2002/018550 patent/WO2002102306A2/en active Application Filing
- 2002-06-14 JP JP2003504820A patent/JP4392238B2/ja not_active Expired - Lifetime
- 2002-06-14 WO PCT/US2002/018549 patent/WO2002102229A2/en active IP Right Grant
- 2002-06-14 ES ES02739838T patent/ES2359494T3/es not_active Expired - Lifetime
- 2002-06-14 KR KR1020097007843A patent/KR100980105B1/ko not_active IP Right Cessation
- 2002-06-14 DE DE60239059T patent/DE60239059D1/de not_active Expired - Lifetime
-
2006
- 2006-04-12 HK HK06104428A patent/HK1083366A1/xx not_active IP Right Cessation
-
2009
- 2009-05-08 JP JP2009113155A patent/JP2009215302A/ja active Pending
-
2013
- 2013-04-04 JP JP2013078654A patent/JP2013139473A/ja active Pending
-
2015
- 2015-08-07 JP JP2015156532A patent/JP2015227369A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE496635T1 (de) | Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sind | |
ATE515575T1 (de) | Verfahren und sonden für den nachweis von krebs | |
ATE194660T1 (de) | Veraendertes gen bei menschlichem colorektalem- krebs | |
ATE470723T1 (de) | Genexpressionsmarker für die prognose von brustkrebs | |
BRPI0214840B8 (pt) | métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa | |
DK1509230T3 (da) | Gefitinib ( IRESSA) til behandlingen af cancer | |
BR9811441A (pt) | Método de proteção para identificar indìviduos com risco de desenvolvimento de doenças associadas a diferentes formas polimórficas do p53 de tipo natural | |
ATE365227T1 (de) | Endometriose marker und verwendung derselben | |
DE69717664D1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
DE50202018D1 (de) | Intrakorporale sonde zur analyse oder diagnose und/oder therapie | |
NI200700126A (es) | Metodos y sistemas para el pronostico y tratamiento de tumores solidos | |
AU2003293141A8 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
ATE458201T1 (de) | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 | |
BRPI0515794A (pt) | processos para avaliar pacientes com leucemia mielóide aguda | |
DE60032784D1 (de) | Markerproteine für prostatakrebs | |
BRPI0412110A (pt) | genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos | |
MXPA03010100A (es) | Tratamiento de la piel. | |
EP1724579A3 (de) | Verfahren zur Diagnose von Prostatakrebs und zur Analyse von Prostatatumoren | |
HUP0303890A2 (hu) | Differenciációs nukleinsavak és polipeptidek inhibitorának prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise | |
Müezzinoğlu et al. | Population standards of prostate specific antigen values in men over 40: community based study in Turkey | |
DK1381696T3 (da) | Methods | |
ATE306559T1 (de) | Verfahren zum screenen von verbindungen mit bioaktivität in organgeweben | |
EA200600012A1 (ru) | Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку | |
DE69912453D1 (de) | Verfahren und materialien zur diagnose instabiler angina | |
AU2003255671A1 (en) | Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |